ReviewCancer immunology, immunotherapy : CII2012
Muscle CARs and TcRs: turbo-charged technologies for the (T cell) masses.
Review in Cancer immunology, immunotherapy : CII, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Improving Tumor Retention of Effector Cells in Adoptive Cell Transfer Therapies by Magnetic Targeting.Pharmaceutics · 2020Review
- Chimeric antigen receptor therapy in hematological malignancies: antigenic targets and their clinical research progress.Annals of hematology · 2020Review
- IL-12 conditioning improves retrovirally mediated transduction efficiency of CD8+ T cells.Cancer gene therapy · 2015Article
- TALEN-mediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer.Gene therapy · 2014Article
- ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells.Cancer immunology, immunotherapy : CII · 2014Article
- Gene therapy on the move.EMBO molecular medicine · 2013Review
- Targeted immunotherapy of cancer with CAR T cells: achievements and challenges.Cancer immunology, immunotherapy : CII · 2012Review
- The first European interdisciplinary ewing sarcoma research summit.Frontiers in oncology · 2012Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A central role for T cells in the control of cancer has been supported by both animal models and clinical observations. Accordingly, the development of potent anti-tumor T cell immunity has been a long-standing objective of immunotherapy. Emerging data from clinical trials that test T cell immune-modulatory agents and genetically engineered and re-targeted T cells have begun to realize the profound potential of T cell immunotherapy to target cancer. This review will focus on a description of recent conceptual and technological advances for the genetic engineering of T cells to enhance anti-tumor T cell immunity through the introduction of tumor-specific receptors, both Chimeric Antigen Receptors (CAR) and T cell receptors (TcR), as well as an overview of emerging data from ongoing clinical trials that highlight the potential of these approaches to effect dramatic and potent anti-tumor immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.